Skip to content

Released Nov 9, 2026, before the open

10-Q filed Nov 9, 2026, 40 days after period end · 0001628280-26-072169

Q3 2026 · 10-Q
Revenue—
Net Income-$71.25MN/M vs Q3 2025N/M vs Q2 2026
EPS Diluted-$1.04N/M vs Q3 2025N/M vs Q2 2026
Operating Income-$75,711,000N/M
Operating Cash Flowderived-$56,129,000N/M
Free Cash Flowderived-$56,792,000N/M

What the release said

Bicara achieved substantial enrollment in the FORTIFI-HN01 pivotal trial in 1L R/M HPV-negative HNSCC and expects topline results from an interim analysis in mid-2027.12

Net loss totaled $71.2 million for the third quarter of 2026 compared to $36.3 million for the third quarter of 2025.3

Research and development expenses were $56.5 million and general and administrative expenses were $19.2 million for the third quarter of 2026.45

Cash, cash equivalents and marketable securities were $442.3 million as of September 30, 2026, expected to fund operations into the first half of 2029.6

Net loss, Q3 2026
$71.2 million Net loss totaled $71.2 million for the third quarter of 2026 compared to $36.3 million for the third quarter of 2025.3
Research and development expenses, Q3 2026
$56.5 million Research and development expenses were $56.5 million for the third quarter of 2026 as compared to $33.0 million for the third quarter of 2025.4
General and administrative expenses, Q3 2026
$19.2 million General and administrative expenses were $19.2 million for the third quarter of 2026 as compared to $7.7 million for the third quarter of 2025.5
Cash, cash equivalents and marketable securities
$442.3 million As of September 30, 2026, compared to $414.8 million as of December 31, 2025.6
Research and development expenses, Q3 2025
$33.0 million Comparison figure for the third quarter of 2025 as stated in the filing.4
General and administrative expenses, Q3 2025
$7.7 million Comparison figure for the third quarter of 2025 as stated in the filing.5
Thaler Agent · checked against the filing
Open the reading ›
The release

Same quarter

MetricQ3 2026Q3 2025Q3 2024Q3 2023
Net Income-$71.25M-$36.33M-$17.48M-$22.85M
EPS Diluted-$1.04-$0.67-$1.60-$38.23

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Bicara Therapeutics Inc. · CIK 2023658 · Engraved from SEC EDGAR